Risk factors associated with high linezolid trough plasma concentrations

References

• Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemoth. 2003;51(Suppl 2):ii916.
   Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629.
   PubMed Web of Science ®Google Scholar
• DeRyke CA, Lodise TP Jr, Rybak MJ, et al. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 2005;128:1414–1422.
   PubMed Web of Science ®Google Scholar
• Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol. 2013;32:1121–1128.
   Google Scholar
• Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs. 2001;61:1–7.
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemoth. 2003;51:1239–1246.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136–1145.
   PubMed Web of Science ®Google Scholar
• Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010;26:571–588.
   PubMed Web of Science ®Google Scholar
• Wiskirchen DE, Shepard A, Kuti JL, et al. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemoth. 2011;55:4170–4175.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17:70–75.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Ag. 2013;41:586–589.
   PubMed Web of Science ®Google Scholar
• Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012;44:60–64.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemoth. 2012;67:2034–2042.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemoth. 2003;47:1824–1831.
   PubMed Web of Science ®Google Scholar
• Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695–698.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Ag. 2010;36:179–181.
   PubMed Web of Science ®Google Scholar
• Soriano A, Gómez J, Gómez L, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol. 2007;26:353–356.
   Google Scholar
• Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18:R148.
   PubMed Web of Science ®Google Scholar
• Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Ag. 2008;31:122–129.
   PubMed Web of Science ®Google Scholar
• Morata L, Cuesta M, Rojas JF, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemoth. 2013;57:1913–1917.
   PubMed Web of Science ®Google Scholar
• Yagi T, Naito T, Doi M, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Ag. 2013;42:329–334.
   PubMed Web of Science ®Google Scholar
• Foj Capell L, Soriano Viladomiu A, Brunet Serra M, et al. Determinación de linezolid en plasma mediante cromatografía líquida de alta resolución para la monitorización terapéutica en pacientes. Rev Lab Clin. 2011;4:207–213.
   Google Scholar
• Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Ag. 2014;44:242–247.
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemoth. 2013;68:2128–2133.
   PubMed Web of Science ®Google Scholar
• Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemoth. 2014;58:2334–2343.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013;53:967–973.
   PubMed Web of Science ®Google Scholar
• Roger C, Muller L, Wallis SC, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemoth. 2016;71:464–470.
   PubMed Web of Science ®Google Scholar
• Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol. 2014;33:1029–1035.
   Google Scholar
• Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–1078.
   PubMed Web of Science ®Google Scholar
• Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31:2126–2133.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemoth. 2011;55:1867–1873.
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemoth. 2010;54:4605–4610.
   PubMed Web of Science ®Google Scholar
• Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–236.
   PubMed Web of Science ®Google Scholar
• Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548–550.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Rekersbrink S, Klotz U, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. N-S Arch Pharmakol. 2001;364:551–557.
   Google Scholar
• Haslam IS, Jones K, Coleman T, et al. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Brit J Pharmacol. 2008;154:246–255.
   PubMed Web of Science ®Google Scholar
• Egle H, Trittler R, Kümmerer K, et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451–453.
   PubMed Web of Science ®Google Scholar
• Pea F, Cojutti P, Dose L, et al. A one-year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2015. doi:10.1111/bcp.12806.
   PubMed Web of Science ®Google Scholar